Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases.

ABSTRACT:

SUBMITTER: Andreev-Drakhlin A 

PROVIDER: S-EPMC7608524 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature